复方苦参注射液联合雷替曲塞和奥沙利铂治疗晚期结肠癌的疗效观察

目的观察复方苦参注射液联合注射用雷替曲塞和注射用奥沙利铂治疗晚期结肠癌的临床疗效。方法选择2014年1月—2015年6月襄阳市中心医院收治的晚期结肠癌患者78例作为研究对象,随机分为对照组和治疗组,每组各39例。对照组患者采用雷替曲塞联合奥沙利铂化疗方案:注射用雷替曲塞3 mg/m2,溶于生理盐水注射液100 m L,第1天静脉滴注;注射用奥沙利铂85 mg/m2,溶于5%葡萄糖注射液500 m L,第1天静脉滴注。治疗组患者在对照组的基础上加用复方苦参注射液20 m L,溶于生理盐水注射液100 m L中,第1~7天静脉滴注。2周为一个周期,所有患者化疗2个周期。观察两组的临床近期疗效和不良反应。结果治疗后,对照组客观缓解率为38.5%,疾病控制率为71.8%;治疗组客观缓解率为46.2%,疾病控制率为87.2%;两组客观缓解率和疾病控制率比较差异具有统计学意义(P0.05)。治疗组的恶心呕吐、转氨酶升高、周围神经毒性和白细胞减少的发生率均显著低于对照组,组间比较差异具有统计学意义(P0.05)。结论复方苦参注射液联合注射用雷替曲塞和注射用奥沙利铂治疗晚期结肠癌能具有较好的临床近期疗效,不良反应减少,值得在临床上进一步推广和应用。

Clinical observation of Compound Kushen Injection combined with raltitrexed and oxaliplatin in treatment of advanced colorectal cancer

Objective To observe the clinical effect of Compound Kushen Injection combined with Raltitrexed for injection and Oxaliplatin for injection in the treatment of advanced colorectal cancer. Methods Patients (78 cases) with advanced colorectal cancer in Xiangyang Central Hospital from January 2014 to June 2015 were randomly divided into control and treatment groups, and each group had 39 cases. The patients in the control group were treated by raltitrexed combined with oxaliplatin chemotherapy. The patients in the control group were iv administered with Raltitrexed for injection in the first day, 3 mg/m² added into 100 mL normal saline. And they were also iv administered with Oxaliplatin for injection in the first day, 85 mg/m² added into 5% glucose injection (500 mL). The patients in the treatment group were iv administered with Compound Kushen Injection on the basis of control group from day 1 to day 7, 20 mL added into 0.9% normal saline (100 mL). One course of treatment included 2 weeks, and two groups were treated for two courses. The short-term efficacy and adverse reactions in two groups were observed and compared. Results After treatment, the objective response rate and disease control rate of control group were 38.5% and 71.8%, while those index of treatment group were 46.2% and 87.2%, and there were differences between two groups (P < 0.05). The incidences of nausea and vomiting, elevation of aminotransferase, peripheral nerve toxicity, and leucopenia in treatment group were significantly lower than those in the control group, and the differences were statistically significant between two groups (P < 0.05). Conclusion Compound Kushen Injection combined with Raltitrexed for injection and Oxaliplatin for injection has good clinical short-term efficacy in treatment of advanced colorectal cancer with less adverse reactions, which has a certain clinical application value.